KELIX bio specializes in the development and distribution of complex generics and biosimilars, targeting high-need populations in emerging markets. By providing affordable access to these advanced pharmaceuticals, the company addresses the significant gap in treatment options for underserved communities.
Funding
$331.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many patients in emerging markets lack access to advanced pharmaceuticals, including complex generics and biosimilars, creating a significant gap in treatment options for underserved communities. This disparity limits the availability of affordable and effective medications for high-need populations.
Solution
KELIX bio develops and distributes complex generics and biosimilars, focusing on providing affordable access to these pharmaceuticals in emerging markets. The company aims to bridge the treatment gap by offering cost-effective alternatives to originator drugs, thereby expanding access to essential medicines for patients who need them most. By specializing in complex formulations and biosimilars, KELIX bio addresses the challenges associated with manufacturing and distributing these specialized products in resource-constrained settings. This approach ensures that patients in emerging markets can benefit from the same advancements in pharmaceutical care as those in developed countries.
Target Audience
The primary target audience includes patients in emerging markets who require access to complex generics and biosimilars, as well as healthcare providers and institutions serving these populations.
Features
- Development of complex generic pharmaceuticals.
- Specialization in biosimilar medications.
- Distribution network focused on emerging markets.
- Focus on affordability and accessibility of advanced treatments.